Free Trial
NASDAQ:DBVT

DBV Technologies Q2 2025 Earnings Report

DBV Technologies logo
$8.99 -0.23 (-2.44%)
As of 01:19 PM Eastern
This is a fair market value price provided by Polygon.io. Learn more.

DBV Technologies EPS Results

Actual EPS
-$1.55
Consensus EPS
-$0.21
Beat/Miss
Missed by -$1.34
One Year Ago EPS
N/A

DBV Technologies Revenue Results

Actual Revenue
$1.74 million
Expected Revenue
$0.64 million
Beat/Miss
Beat by +$1.09 million
YoY Revenue Growth
N/A

DBV Technologies Announcement Details

Quarter
Q2 2025
Time
Before Market Opens
Conference Call Date
Tuesday, July 29, 2025
Conference Call Time
4:00PM ET

Upcoming Earnings

DBV Technologies' Q3 2025 earnings is scheduled for Wednesday, November 5, 2025, with a conference call scheduled at 2:00 AM ET. Check back for transcripts, audio, and key financial metrics as they become available.

Earnings Documents

DBV Technologies Earnings Headlines

Buffett, Gates and Bezos Dumping Stocks
The world's wealthiest individuals are making huge moves with their money. Warren Buffett just liquidated billions of shares. Bill Gates sold 500,000 shares of Microsoft. Jeff Bezos filed to sell Amazon shares worth $4.8 billion. What is going on? One multi-millionaire believes they are preparing for a catastrophic event. But not a crash, bank run, or recession. It’s something we haven’t see in America for more than a century.tc pixel
See More DBV Technologies Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like DBV Technologies? Sign up for Earnings360's daily newsletter to receive timely earnings updates on DBV Technologies and other key companies, straight to your email.

About DBV Technologies

DBV Technologies (NASDAQ:DBVT) SA is a clinical-stage biopharmaceutical company engaged in developing immunotherapies for allergic diseases. The company specializes in epicutaneous immunotherapy, leveraging its proprietary Viaskin platform to deliver biologically active compounds across intact skin without needles or injections. Through this approach, DBV aims to modulate patients’ immune response to specific allergens, offering a potentially safer and more convenient alternative to traditional therapies.

The company’s lead product candidate, Viaskin Peanut, is designed for the treatment of peanut allergy in children and adolescents. Viaskin Peanut is being evaluated in global clinical trials to assess its ability to reduce allergic reactions and improve patients’ threshold of reactivity to peanut exposure. DBV is also exploring the applicability of its technologies to other food allergens, including cow’s milk and egg, as part of its long-term pipeline strategy.

Founded in 2002 and headquartered in Montrouge, France, DBV Technologies maintains research and development operations in Cambridge, Massachusetts, reflecting its transatlantic focus. The company has established alliances with academic institutions and leading allergy research centers to advance its clinical programs and expand its scientific expertise. Its development activities span North America, Europe and other regions where food allergy represents a significant public health challenge.

Under the leadership of President and Chief Executive Officer Daniel Tasse, DBV Technologies has navigated multiple phases of clinical development and regulatory interactions. The company continues to engage with health authorities to define approval pathways and to establish its proprietary immunotherapy platform as a new standard of care for allergic diseases.

View DBV Technologies Profile

More Earnings Resources from MarketBeat